Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-09-25 | 2024-06 | 0 | N/A | N/A | N/A |
2024-05-15 | 2024-03 | 0 | -0.52 | N/A | N/A |
2024-02-14 | 2023-12 | 0 | -0.04 | N/A | N/A |
2023-11-14 | 2023-09 | 0 | -1.48 | N/A | N/A |
2023-09-27 | 2023-06 | 0 | 0.16 | N/A | N/A |
2023-05-11 | 2023-03 | 0 | -1.93 | N/A | N/A |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-08-08 | Maxim Group | Upgrade | Buy | |
2023-05-30 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2021-04-15 | CANTRELL GARY V. | Director | 204.09K | Stock Award(Grant) |
2023-06-13 | DISBROW JOSHUA R. | Chief Executive Officer | 71.59K | Purchase |
2023-08-10 | DOCKERY CARL C | Director | 8.94K | Stock Award(Grant) |
2021-04-07 | HECHT BETH P | Director | 9.05K | Stock Award(Grant) |
2023-08-15 | JAIN ABHINAV | Director | 8.00K | Stock Award(Grant) |
2023-08-10 | LIU VIVIAN H | Director | 1.84K | Stock Award(Grant) |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Nantahala Capital Management, LLC | 1.09M | 1.74M | 19.65% |
2023-06-29 | Stonepine Capital Management, LLC | 472.37K | 755.79K | 8.54% |
2023-06-29 | Renaissance Technologies, LLC | 57.32K | 91.72K | 1.04% |
2023-06-29 | Blackrock Inc. | 24.06K | 38.49K | 0.44% |
2023-06-29 | Acadian Asset Management. LLC | 22.54K | 36.06K | 0.41% |
2023-06-29 | Prudential Financial, Inc. | 19.58K | 31.32K | 0.35% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Extended Market Index Fund | 9.99K | 15.99K | 0.18% |
2023-05-30 | Fidelity Extended Market Index Fund | 8.71K | 14.55K | 0.16% |
2023-05-30 | Fidelity Series Total Market Index Fund | 1.59K | 2.66K | 0.03% |
2023-05-30 | Fidelity Total Market Index Fund | 1.59K | 2.65K | 0.03% |
2023-08-30 | iShares Core S&P Total U.S. Stock Market ETF | 1.27K | 2.15K | 0.02% |
Split | Date |
---|---|
1 : 20 | 2023-01-06 |
1 : 10 | 2020-12-09 |
1 : 20 | 2018-08-13 |
1 : 20 | 2017-08-29 |
1 : 12 | 2016-07-01 |
82 : 1000 | 2015-06-10 |
-
-
The float is insane is small minds talking. Companies that will push for buyout always dilute so they have leverage over deal. Increase institutions and then push price up. Rookies. Josh is creating this company to sell
-
Healight gets fda approval and Josh sells Aytu for 3-5 billion n my opinion !!! $20-$40 a share hopefully.
-
Why RS? We have positive earnings coming, we have fda/eua on pinnacle test and we have fda/eua Healight coming. Why would we need to do RS
-
Rock n roll, love opportunities to double down. Now I wait !!!
-
Doubled down
-
I am so happy I got to double down under my average. We going up soon. Maybe not today but it is coming
-
-
Yes please sell me shares for under 1.20. I’m buying low ones all day
-
True bulls are watching to double down. Great info yesterday and company headed in right direction. Go ahead wait to buy for more later. Way too much coming out sooner than later
-
-
Clowns. With that earning, institution buying will keep going up, Healight will come out, pinnacle test sales will start up. Not sure what you all want better than that. 700 percent increase revenues lol. Clowns
-
All u jokers that complain for a living, check back in a year or two and hear of stories when we all sold Aytu for $25 plus when he sold company for billions. Lol. Spoiled brats need instant gratification daily to feel worthy lol. It is cool if you day trade but damn shut up talking shit to everyone else who is here for Healight and longer haul. The earnings were what we expected em to be. Good. And now we keep moving forward with good news. Price change occurs on big test sales or Healight and future earnings. Next earnings only weeks away unless they postpone and it will be bigger.
-
Fourth Quarter Fiscal 2020 Financial Highlights
Q4 Net Revenue increased 82% sequentially, and 766% year-over-year to $14.9 million
Highest revenue quarter to date is more than 2X entire fiscal 2019 revenue
Q4 Consumer Health Net Revenue was $6.9 million, compared to $3.5 in Q3
Q4 Rx Net Revenue was $7.9 million, compared to $4.7 in Q3
Q4 Net loss of ($3.1) million and Q4 Adjusted EBITDA of ($1.7) million
Cash, cash equivalents and restricted cash of $48.3 million on June 30, 2020, after fully extinguishing the $15 million Deerfield balloon payment obligation. -
Trump turn around and mention Healight and you all will be sucking his shit again lol
-
Would rather have Supreme Court judge placed in
-
-
-
Aytu BioPharma, Inc. (AYTU) Q3 2024 Earnings Call Transcript
seekingalpha.com • -
Aytu BioPharma, Inc. (AYTU) Q2 2024 Earnings Call Transcript
seekingalpha.com • -
Aytu BioPharma, Inc. (AYTU) Q1 2024 Earnings Call Transcript
seekingalpha.com • -
Aytu BioPharma Reports Fiscal 2024 First Quarter Financial Results
accesswire.com • -
Best Penny Stocks? 4 Hot Stocks With News This Week
pennystocks.com • -
Aytu BioPharma, Inc. (AYTU) Q4 2023 Earnings Call Transcript
seekingalpha.com •